Showing 1 – 7 of 7
Best Match | Most Recent | Oldest |
  • Image of the Month—Diagnosis

    Abstract Full Text
    free access
    Arch Surg. 2010; 145(10):1018-1018. doi: 10.1001/archsurg.2010.221-b
  • Image of the Month—Quiz Case

    Abstract Full Text
    free access
    Arch Surg. 2010; 145(10):1017-1017. doi: 10.1001/archsurg.2010.221-a
  • Antiphospholipid Antibodies and Arterial Thrombosis: Case Reports and a Review of the Literature

    Abstract Full Text
    Arch Surg. 1992; 127(3):342-346. doi: 10.1001/archsurg.1992.01420030116022
  • Females With Subclavian Vein Thrombosis May Have an Increased Risk of Hypercoagulability

    Abstract Full Text
    free access
    JAMA Surg. 2013; 148(1):44-49. doi: 10.1001/jamasurgery.2013.406
    To determine the prevalence of hypercoagulability in patients with Paget-Schroetter syndrome undergoing first rib resection and scalenectomy for subclavian vein thrombosis Likes and colleagues retrospectively reviewed the costs and clinical outcomes.
  • Systemic Inflammatory Disease and Its Association With Type II Endoleak and Late Interventions After Endovascular Aneurysm Repair

    Abstract Full Text
    JAMA Surg. 2016; 151(2):147-153. doi: 10.1001/jamasurg.2015.3219

    This case series reports that patients with systemic inflammatory disease are at high risk for postoperative complications, type II endoleak, sac expansion, and additional interventions after endovascular aneurysm repair.

  • Progressive Soft-Tissue Necrosis

    Abstract Full Text
    JAMA Surg. 2014; 149(2):211-212. doi: 10.1001/2013.jamasurg.356
  • Prevalence and Implications of Preinjury Warfarin Use: An Analysis of the National Trauma Databank

    Abstract Full Text
    free access
    Arch Surg. 2011; 146(5):565-570. doi: 10.1001/archsurg.2010.313

    To describe the prevalence of preinjury warfarin use in a large national sample of trauma patients and to define the relationship between preinjury warfarin use and mortality.


    Retrospective cohort study.


    The National Trauma Databank (7.1).


    All patients admitted to eligible trauma centers during the study period; 1 230 422 patients (36 270 warfarin users) from 402 centers were eligible for analysis.

    Main Outcome Measures

    Prevalence of warfarin use and all-cause in-hospital mortality. Multivariate logistic regression was used to estimate the odds ratio (OR) for mortality associated with preinjury warfarin use.


    Warfarin use increased among all patients from 2.3% in 2002 to 4.0% in 2006 (P < .001), and in patients older than 65 years, use increased from 7.3% in 2002 to 12.8% in 2006 (P < .001). Among all patients, 9.3% of warfarin users died compared with only 4.8% of nonusers (OR, 2.02; 95% confidence interval [CI], 1.95-2.10; P < .001). After adjusting for important covariates, warfarin use was associated with increased mortality among all patients (OR, 1.72; 95% CI, 1.63-1.81; P < .001) and patients 65 years and older (OR, 1.38; 95% CI, 1.30-1.47; P < .001).


    Warfarin use is common among injured patients and its prevalence has increased each year since 2002. Its use is a powerful marker of mortality risk, and even after adjusting for confounding comorbidities, it is associated with a significant increase in death.